The Food and Drug Administration yesterday approved a new drug application for propofol injectable emulsion, an intravenous general anesthetic and sedation drug in short supply.

“The agency recognizes there is increased demand for certain products, such as propofol injectable emulsion, during the novel coronavirus pandemic, and remains committed to facilitating access to safe and effective medical products to help address critical needs of the American public,” the agency said.

Related News Articles

Perspective
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on…
Headline
“The COVID-19 pandemic has proved that crisis tends to be a driver of innovation,” writes Jonathan Bandel, vice president of strategy and innovation for New…
Headline
The Food and Drug Administration Wednesday updated its guidance on enforcement policy for non-invasive remote monitoring devices that support patient…
Headline
The Centers for Medicare & Medicaid Services yesterday announced an interim final rule establishing additional Medicare hospital payment to support…
#HealthCareInnovation Thursday Blog
When the first case of coronavirus was confirmed in New Rochelle, New York, in early March, White Plains Hospital, a 292-bed tertiary care hospital located…
Headline
In partnership with the AHA’s Center for Health Innovation and other national health care organizations, the Centers for Disease Control and Prevention today…